Myoclonic-Atonic Epilepsy Caused by a Novel de Novo Heterozygous Missense Variant in the SLC6A1 Gene: Brief Discussion of the Literature and Detailed Case Description of a Severely Intellectually Disabled Adult Male Patient
Open Access
- 23 December 2022
- journal article
- research article
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 15, 753-759
Abstract
Introduction: Diagnostic exome sequencing has yielded over the past decades a great number of molecular diagnoses for genetic disorders in which both intellectual disability and epilepsy are present. One of these syndromes is myoclonic-atonic epilepsy (MAE) that is caused by pathogenic variants in the SLC6A1 gene located at 3p25.3. The most relevant clinical characteristics are intellectual disability, several forms of mostly treatment-resistant epilepsy starting at young age, serious disinhibitory behavioural problems, language impairment, higher pain tolerance, and symptoms from the autism spectrum, all in the absence of any consistent dysmorphism or malformation. Methods: After an overview of the literature, here, the developmental trajectory of a 55-year-old severely intellectually disabled male with therapy-resistant epilepsy and aggressive outburst is reported in detail, in whom no etiological diagnosis had been performed. Next to genetic, neurological, and neuropsychiatric examination, psychological assessment with validated instruments was performed. Results: Exome sequencing and targeted analysis of the patient and both his parents demonstrated a de novo missense variant in the SLC6A1 gene which was never before described in the literature nor in control databases. The phenotypical presentation of the patient with treatment-resistant epilepsy, especially absences and myoclonic seizures, as well as sleep disturbances and autism, corresponds with a diagnosis of MAE. Discussion: This case stresses that exome sequencing should be the first-tier diagnostic test for patients with unexplained neurodevelopmental disorders, regardless of their age, and that as yet the most suitable approach is the formation of an interdisciplinary team for treatment design and clinical management.Keywords
This publication has 24 references indexed in Scilit:
- Defining the phenotypic spectrum of SLC6A1 mutationsEpilepsia, 2018
- Epilepsy-associated genesSeizure: European Journal of Epilepsy, 2017
- Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic SeizuresThe American Journal of Human Genetics, 2015
- 3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behaviorAmerican Journal of Medical Genetics Part A, 2014
- Structure, function, and plasticity of GABA transportersFrontiers in Cellular Neuroscience, 2014
- A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous DiseasesHuman Mutation, 2013
- Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing studyThe Lancet, 2012
- De novo mutations revealed by whole-exome sequencing are strongly associated with autismNature, 2012
- Enhanced tonic GABAA inhibition in typical absence epilepsyNature Medicine, 2009
- Centrencephalic Myoclonic-Astatic Petit Mal1– Clinical and genetic investigationsNeuropediatrics, 1970